Mohamed Benharouga

Prof. Dr. Mohamed Benharouga

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
NANadia Alfaidy
Nadia Alfaidy
SCSylvain Chauvet
Sylvain Chauvet
SDSandrine Donadio-Andrei
Sandrine Donadio-Andrei
ASAude Salomon
Aude Salomon
YSYasmina Saoudi
Yasmina Saoudi
MBMohamed Benharouga
Mohamed Benharouga
Aim: It has been convincingly shown that oxidative stress and toxicity by deregulated metals, such as copper (Cu), are tightly linked to the development of pre-eclampsia and intrauterine growth retardation (IUGR), the most threatening pathologies of human pregnancy. However, mechanisms implemented to control these effects are far from being understood. Among proteins that bind Cu and insure cellular protection against oxidative stress is the cellular prion protein (PrP C ), a glycosyl phosphatidyl inositol-anchored glycoprotein, which we reported to be highly expressed in human placenta. Herein, we investigated the pathophysiological role of PrP C in Cu and oxidative stress homeostasis in vitro using human placenta and trophoblast cells, and in vivo using three strains of mice (C57Bl6, PrP C knockout mice [PrP −/− ], and PrP C overexpressing mice [Tga20]). Results: At the cellular level, PrP C protection against oxidative stress was established in multiple angiogenic processes: proliferation, migration, and tube-like organization. For the animal models, lack (PrP −/− ) or overexpression (Tga20) of PrP C in gravid mice caused severe IUGR that was correlated with a decrease in litter size, changes in Cu homeostasis, increase in oxidative stress response, development of hypoxic environment, failure in placental function, and maintenance of growth defects of the offspring even 7.5 months after delivery. Innovation: PrP C could serve as a marker for the idiopathic IUGR disease. Conclusion: These findings demonstrate the stress-protective role of PrP C during development, and propose PrP C dysregulation as a novel causative element of IUGR. Antioxid. Redox Signal . 18, 400–411.

10 October 2015 in Hormone Molecular Biology and Clinical Investigation
Verified
Journal Article
Closed access
WTWael Traboulsi
Wael Traboulsi
SBSophie Brouillet
Sophie Brouillet
FSFrederic Sergent
Frederic Sergent
HBHoussine Boufettal
Houssine Boufettal
NSNaima Samouh
Naima Samouh
Nadia AlfaidyNadia Alfaidy
Nadia Alfaidy
Prokineticin 1 (PROK1) and (PROK2), are two closely related proteins that were identified as the mammalian homologs of their two amphibian homologs, mamba intestinal toxin (MIT-1) and Bv8. PROKs activate two G-protein linked receptors (prokineticin receptor 1 and 2, PROKR1 and PROKR2). Both PROK1 and PROK2 have been found to regulate a stunning array of biological functions. In particular, PROKs stimulate gastrointestinal motility, thus accounting for their family name “prokineticins”. PROK1 acts as a potent angiogenic mitogen, thus earning its other name, endocrine gland-derived vascular endothelial factor. In contrast, PROK2 signaling pathway has been shown to be a critical regulator of olfactory bulb morphogenesis and sexual maturation. During the last decade, strong evidences established the key roles of prokineticins in the control of human central and peripheral reproductive processes. PROKs act as main regulators of the physiological functions of the ovary, uterus, placenta, and testis, with marked dysfunctions in various pathological conditions such as recurrent pregnancy loss, and preeclampsia. PROKs have also been associated to the tumor development of some of these organs. In the central system, prokineticins control the migration of GnRH neurons, a key process that controls reproductive functions. Importantly, mutations in PROK2 and PROKR2 are associated to the development of Kallmann syndrome, with direct consequences on the reproductive system. This review describes the finely tuned actions of prokineticins in the control of the central and peripheral reproductive processes. Also, it discusses future research directions for the use of these cytokines as diagnostic markers for several reproductive diseases.

8 September 2023 in Pharmacological Reviews
Verified
Journal Article
Open access
PDF file
Martina VincenziMartina Vincenzi
Martina Vincenzi
AKAmin Kremić
Amin Kremić
AJAppoline Jouve
Appoline Jouve
Roberta LattanziRoberta Lattanzi
Roberta Lattanzi
Rossella MieleRossella Miele
Rossella Miele
Canan NebigilCanan Nebigil
Canan Nebigil
The prokineticins (PKs) were discovered approximately 20 years ago as small peptides inducing gut contractility. Today, they are established as angiogenic, anorectic, and proinflammatory cytokines, chemokines, hormones, and neuropeptides involved in variety of physiologic and pathophysiological pathways. Their altered expression or mutations implicated in several diseases make them a potential biomarker. Their G-protein coupled receptors, PKR1 and PKR2, have divergent roles that can be therapeutic target for treatment of cardiovascular, metabolic, and neural diseases as well as pain and cancer. This article reviews and summarizes our current knowledge of PK family functions from development of heart and brain to regulation of homeostasis in health and diseases. Finally, the review summarizes the established roles of the endogenous peptides, synthetic peptides and the selective ligands of PKR1 and PKR2, and nonpeptide orthostatic and allosteric modulator of the receptors in preclinical disease models. The present review emphasizes the ambiguous aspects and gaps in our knowledge of functions of PKR ligands and elucidates future perspectives for PK research. Significance Statement This review provides an in-depth view of the prokineticin family and PK receptors that can be active without their endogenous ligand and exhibits “constitutive” activity in diseases. Their non- peptide ligands display promising effects in several preclinical disease models. PKs can be the diagnostic biomarker of several diseases. A thorough understanding of the role of prokineticin family and their receptor types in health and diseases is critical to develop novel therapeutic strategies with safety concerns.

26 January 2007 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
BKB. De Keukeleire
B. De Keukeleire
SDS. Donadio
S. Donadio
JMJ. Micoud
J. Micoud
DLDelphine Lechardeur
Delphine Lechardeur
MBMohamed Benharouga
Mohamed Benharouga

15 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DRDéborah Reynaud
Déborah Reynaud
RNRoland Abi Nahed
Roland Abi Nahed
NLNicolas LEMAITRE
Nicolas LEMAITRE
PBPierre-Adrien Bolze
Pierre-Adrien Bolze
WTWael Traboulsi
Wael Traboulsi
Nadia AlfaidyNadia Alfaidy
Nadia Alfaidy
The inflammatory gene NLRP7 is the major gene responsible for recurrent complete hydatidiform moles (CHM), an abnormal pregnancy that can develop into gestational choriocarcinoma (CC). However, the role of NLRP7 in the development and immune tolerance of CC has not been investigated. Three approaches were employed to define the role of NLRP7 in CC development: (i) a clinical study that analyzed human placenta and sera collected from women with normal pregnancies, CHM or CC; (ii) an in vitro study that investigated the impact of NLRP7 knockdown on tumor growth and organization; and (iii) an in vivo study that used two CC mouse models, including an orthotopic model. NLRP7 and circulating inflammatory cytokines were upregulated in tumor cells and in CHM and CC. In tumor cells, NLRP7 functions in an inflammasome-independent manner and promoted their proliferation and 3D organization. Gravid mice placentas injected with CC cells invalidated for NLRP7, exhibited higher maternal immune response, developed smaller tumors, and displayed less metastases. Our data characterized the critical role of NLRP7 in CC and provided evidence of its contribution to the development of an immunosuppressive maternal microenvironment that not only downregulates the maternal immune response but also fosters the growth and progression of CC.

24 January 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
RNRoland Abi Nahed
Roland Abi Nahed
MMMaya Elkhoury Mikhael
Maya Elkhoury Mikhael
DRDéborah Reynaud
Déborah Reynaud
CCConstance Collet
Constance Collet
NLNicolas LEMAITRE
Nicolas LEMAITRE
MBMohamed Benharouga
Mohamed Benharouga
Gestational choriocarcinoma (CC) is an aggressive cancer that develops upon the occurrence of abnormal pregnancies such as Hydatidiform moles (HMs) or upon non-molar pregnancies. CC cells often metastasize in multiple organs and can cause maternal death. Recent studies have established an association between recurrent HMs and mutations in the Nlrp7 gene. NLRP7 is a member of a new family of proteins that contributes to innate immune processes. Depending on its level of expression, NLRP7 can function in an inflammasome-dependent or independent pathway. To date, the role of NLRP7 in normal and in malignant human placentation remains to be elucidated. We have recently demonstrated that NLRP7 is overexpressed in CC trophoblast cells and may contribute to their acquisition of immune tolerance via the regulation of key immune tolerance-associated factors, namely HLA family, βCG and PD-L1. We have also demonstrated that NLRP7 increases trophoblast proliferation and decreases their differentiation, both in normal and tumor conditions. Actual findings suggest that NLRP7 expression may ensure a strong tolerance of the trophoblast by the maternal immune system during normal pregnancy and may directly affect the behavior and aggressiveness of malignant trophoblast cells. The proposed review summarizes recent advances in the understanding of the significance of NLRP7 overexpression in CC and discusses its multifaceted roles, including its function in an inflammasome-dependent or independent pathways.